Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2019

View Archived Issues

Using promiscuity to identify high-commitment targets

Local vaccine can induce global remission

Design of EBNA1-specific inhibitors suppressing Epstein-Barr virus-driven tumor growth

CCR1 is differentially expressed across ovarian cancer subtypes

Phase II dose of cancer vaccine IMU-131 identified in HER2/neu-overexpressing stomach cancer trial

Phase II study of AXS-05 for smoking cessation meets prespecified primary endpoint

Alnylam initiates global phase III pediatric ILLUMINATE-B study

Clinical program update on ADVM-022 gene therapy

Synapse formation important for ketamine durability

Preclinical characterization of PF-06882961

S100B SNPs and haplotypes as markers of acute and chronic pain in sickle cell disease

RTI-1092663 improves metabolic syndrome in mice

Shenyang Pharmaceutical University patents neuraminidase inhibitors

Hansa receives ethics and regulatory clearance to initiate phase II study of imlifidase in GBS

FDA gives clearance to initiate phase II/III study of ARO-AAT for AATD liver disease

Diamyd Medical presents 30-month results from phase IIa EDCR study

MediciNova moves forward with a phase III study of MN-166 in ALS

CStone Pharmaceuticals announces dosing of first patient in phase III GEMSTONE-303 study

Positive interim results presented from phase I study of CERC-301

Positive 12-month data presented from phase II study of Clascoterone

Interim results presented from phase II study of chikungunya virus vaccine candidate

Cortexyme launches phase II/III study of COR-388 in subjects with Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...